Robert C. Smith, MD, PhD, is affiliated with the Nathan S. Kline Institute for Psychiatric Research and the Department of Psychiatry at New York University School of Medicine. His published work focuses on the treatment of schizophrenia and schizoaffective disorders, particularly investigating the effects and safety of antipsychotic medications such as risperidone and olanzapine. He has also studied metabolic disorders related to antipsychotic use, including glucose metabolism and hyperglycemia. His research spans from 1996 to 2025 and includes collaborative studies with several co-authors.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
